Travere's FILSPARI for IgAN Wins FDA Approval, Stock Up 5.7%

Sep 6, 2024, 04:39 AM

Travere Therapeutics has announced that its drug FILSPARI (sparsentan) has received full approval from the FDA for treating IgA nephropathy (IgAN). FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgAN. Following the approval, Travere Therapeutics' stock (TVTX) saw a pre-market gain of 5.7%.